Skip to main content

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Publication ,  Journal Article
Byrd, JC; Mrózek, K; Dodge, RK; Carroll, AJ; Edwards, CG; Arthur, DC; Pettenati, MJ; Patil, SR; Rao, KW; Watson, MS; Koduru, PRK; Moore, JO ...
Published in: Blood
December 15, 2002

We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year overall survival (OS). All patients received similar induction therapy. Median follow-up for surviving patients was 8.3 years. Nonprioritized cytogenetics distinguished t(8;21) and inv(16)/t(16;16) as conferring a significantly better prognosis than normal karyotype. Prognostic impact of many abnormalities could not be determined independently because of their association with complex karyotype. Neither complex karyotype nor secondary aberrations affected outcome of patients with t(8;21), inv(16)/t(16;16), or t(9;11). Among other patients, those with complex karyotypes had significantly worse outcomes than cytogenetically normal patients. Based on outcome for specific cytogenetic abnormalities and karyotype complexity, patients were divided into 3 risk groups: favorable (CR 88%, CIR 54%, OS 55%), intermediate (CR 67%, CIR 67%, OS 24%), and adverse (CR 32%, CIR 92%, OS 5%). Multivariate analyses confirmed the major contribution of cytogenetics to the probability of attaining CR, CIR, and OS. For the adverse-risk group, the probability of achieving CR was 4.0 and 11.9 times lower, the probability of relapse 3.0 and 4.4 times higher, and the risk of death 2.1 and 4.3 times higher than those for the intermediate and favorable groups, respectively. We conclude that although the prognostic impact of many recurring abnormalities has not been ascertained independently of complex karyotype, cytogenetics is among the most useful factors predicting attainment of CR, CIR, and long-term survival in adult AML.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

December 15, 2002

Volume

100

Issue

13

Start / End Page

4325 / 4336

Location

United States

Related Subject Headings

  • Trisomy
  • Treatment Outcome
  • Translocation, Genetic
  • Survival Analysis
  • Risk Factors
  • Remission Induction
  • Recurrence
  • Prospective Studies
  • Life Tables
  • Leukemia, Myeloid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Byrd, J. C., Mrózek, K., Dodge, R. K., Carroll, A. J., Edwards, C. G., Arthur, D. C., … Cancer and Leukemia Group B (CALGB 8461), . (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100(13), 4325–4336. https://doi.org/10.1182/blood-2002-03-0772
Byrd, John C., Krzysztof Mrózek, Richard K. Dodge, Andrew J. Carroll, Colin G. Edwards, Diane C. Arthur, Mark J. Pettenati, et al. “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).Blood 100, no. 13 (December 15, 2002): 4325–36. https://doi.org/10.1182/blood-2002-03-0772.
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325–4336.

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

December 15, 2002

Volume

100

Issue

13

Start / End Page

4325 / 4336

Location

United States

Related Subject Headings

  • Trisomy
  • Treatment Outcome
  • Translocation, Genetic
  • Survival Analysis
  • Risk Factors
  • Remission Induction
  • Recurrence
  • Prospective Studies
  • Life Tables
  • Leukemia, Myeloid